Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has entered into a research agreement with UCSF to advance the pre-clinical development of a novel PSMA ligand for prostate cancer diagnosis and therapy, highlighting the potential of theranostic molecules in improving cancer treatment outcomes [1][2]. Company Overview - Shuttle Pharmaceuticals is a specialty pharmaceutical company founded in 2012, focused on enhancing outcomes for cancer patients undergoing radiation therapy by developing therapies that maximize effectiveness while minimizing side effects [5]. Research Agreement Details - The agreement with UCSF aims to develop a boron-containing PSMA ligand, PSMA-B, which has shown nanomolar binding activity to PSMA and is being evaluated for its potential as a sensitizer in proton therapy for prostate cancer [2]. - UCSF researchers will work on producing a specific probe and investigating its binding properties and diagnostic potential across various prostate cancer phenotypes [2]. Market Opportunity - There is a significant market opportunity for PSMA ligands in prostate cancer diagnosis and treatment, particularly for metastatic castration-resistant prostate cancer, with the global PSMA PET imaging market projected to grow from 2.0 billion by 2030 [3]. - The targeted radiopharmaceutical treatment Pluvicto® for PSMA-positive metastatic prostate cancer is expected to reach a market size of $2 billion [3]. Future Outlook - The collaboration with UCSF is expected to advance the development of the PSMA-B ligand, which could play a crucial role in the future of prostate cancer diagnosis and treatment [4].
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program